- Stocks
- Healthcare
- NASDAQ: BMRN

Price (delayed)

$81.83

Market cap

$14.85B

P/E Ratio

17.37

Dividend/share

N/A

EPS

$4.71

Enterprise value

$15.29B

The equity has grown by 32% YoY and by 25% from the previous quarter

The revenue has grown by 16% YoY

Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ

The debt has soared by 72% year-on-year

BMRN's gross margin is down by 7% year-on-year and by 6% since the previous quarter

What are the main financial stats of BMRN

Market
Valuations
Earnings

Shares outstanding

181.53M

Market cap

$14.85B

Enterprise value

$15.29B

Price to earnings (P/E)

17.37

Price to book (P/B)

3.66

Price to sales (P/S)

7.96

EV/EBIT

781.08

EV/EBITDA

124.11

EV/Sales

8.21

Revenue

$1.86B

EBIT

$19.57M

EBITDA

$123.18M

Free cash flow

$89.18M

Per share
Balance sheet
Liquidity

EPS

$4.71

Free cash flow per share

$0.49

Book value per share

$22.35

Revenue per share

$10.28

TBVPS

$30.55

Total assets

$6.16B

Total liabilities

$2.1B

Debt

$1.45B

Equity

$4.05B

Working capital

$1.88B

Debt to equity

0.36

Current ratio

3.2

Quick ratio

2.24

Net debt/EBITDA

3.51

Margins
Efficiency
Dividend

EBITDA margin

6.6%

Gross margin

73.5%

Net margin

45.7%

Operating margin

-0.1%

Return on assets

16.3%

Return on equity

25%

Return on invested capital

0.5%

Return on capital employed

0.4%

Return on sales

1.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Biomarin Pharmaceutical stock price performed over time

Intraday

-1.79%

1 week

-1.73%

1 month

-8.03%

1 year

-10.08%

YTD

-6.68%

QTD

-6.68%

How have Biomarin Pharmaceutical's revenue and profit performed over time

Revenue

$1.86B

Gross profit

$1.37B

Operating income

-$1.09M

Net income

$852.03M

Gross margin

73.5%

Net margin

45.7%

Biomarin Pharmaceutical's operating margin has plunged by 103% from the previous quarter but it has soared by 99% YoY

The operating income has dropped by 102% since the previous quarter but it has surged by 99% year-on-year

The revenue has grown by 16% YoY

Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ

What is Biomarin Pharmaceutical's growth rate over time

What is Biomarin Pharmaceutical stock price valuation

P/E

17.37

P/B

3.66

P/S

7.96

EV/EBIT

781.08

EV/EBITDA

124.11

EV/Sales

8.21

The stock's price to book (P/B) is 32% less than its 5-year quarterly average of 5.4 and 27% less than its last 4 quarters average of 5.0

The equity has grown by 32% YoY and by 25% from the previous quarter

BMRN's price to sales (P/S) is 29% less than its 5-year quarterly average of 11.2 and 13% less than its last 4 quarters average of 9.2

The revenue has grown by 16% YoY

How efficient is Biomarin Pharmaceutical business performance

Biomarin Pharmaceutical's ROIC has soared by 118% YoY but it has plunged by 77% from the previous quarter

Biomarin Pharmaceutical's return on sales has surged by 117% YoY but it has shrunk by 76% QoQ

What is BMRN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BMRN.

How did Biomarin Pharmaceutical financials performed over time

The total assets is 193% more than the total liabilities

The total assets has grown by 35% YoY and by 16% from the previous quarter

The debt is 64% smaller than the equity

BMRN's debt to equity is up by 33% year-on-year but it is down by 20% since the previous quarter

The equity has grown by 32% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.